Clinical trial NCT04511871 involves CCT303-406 (a HER2 antagonist) CAR-modified autologous T cells, evaluating their safety, tolerability, and anti-tumor activity in patients with recurrent or refractory HER2-positive solid tumors. The gene discussed is ERBB2; the disease is neoplasm.